|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients显示文摘AIM:To investigate the efficacy and safety of capecitabine plus irinotecan±bevacizumab in advanced or metastatic colorectal cancer patients. METHODS:Forty six patients with previously untreated,locally-advanced or metastatic colorectal cancer(mCRC) were recruited between 2001-2006 in a prospective open-label phaseⅡtrial,in German community-based outpatient clinics.Patients received a standard capecitabine plus irinotecan(CAPIRI) or CAPIRI plus bevacizumab(CAPIRI-BEV) regimen every 3 wk. Dose reductions were mandatory from the first cycle in cases of>grade 2 toxicity.The treatment choice of bevacizumab was at the discretion of the physician.Theprimary endpoints were response and toxicity and secondary endpoints included progression-free survival and overall survival. RESULTS:In the CAPIRI group vs the CAPRI-Bev group there were more female than male patients(47% vs 24%) ,and more patients had colon as the primary tumor site(58.8%vs 48.2%) with fewer patients having sigmoid colon as primary tumor site(5.9%vs 20.7%) .Grade 3/4 toxicity was higher with CAPIRI than CAPIRI-Bev:82%vs 58.6%.Partial response rates were 29.4%and 34.5%,and tumor control rates were 70.6%and 75.9%,respectively.No complete responses were observed.The median progression-free survival was 11.4 mo and 12.8 mo for CAPIRI and CAPIRI-Bev,respectively.The median overall survival for CAPIRI was 15 mo(458 d) and for CAPIRI-Bev 24 mo(733 d) .These differences were not statistically different.In the CAPIRI-Bev,group,two patients underwent a full secondary tumor resection after treatment,whereas in the CAPIRI group no cases underwent this procedure. CONCLUSION:Both regimens were well tolerated and offered effective tumor growth control in this outpatient setting.Severe gastrointestinal toxicities and thromboembolic events were rare and if observed were never fatal. | Markus Moehler Martin F Sprinzl Murad Abdelfattah Carl C Schimanski Bernd Adami Werner Godderz Klaus Majer Dimitri Flieger Andreas Teufel Juergen Siebler Thomas Hoehler Peter R Galle Stephan Kanzler | 2009 | World Journal of Gastroenterology2009，15，4： | 10 |
| 2 | Optimal performance and delocalization in NK fitness landscapes显示文摘 | Campos P R A Adami C Wilke C O | 2002 | Physica A2002，304，34： | 1 |
| 3 | Reduction criterion for separability显示文摘 | Cerf N J Adami C Gingrich R M | 1999 | Phys Rev A1999，60，： | 1 |
| 4 | Peptidemediated gene delivery:influence of peptide structure on gene expression 显示文摘 | WADHWA M S COLLARD W T ADAMI R C | 1997 | Bioconjug Chem1997，8，1： | 1 |
| 5 | Sustained vertebral fracture risk reduction after withdrawal of teriparatide in post-menopausal women with osteoporosis显示文摘 | Lindsay R Scheele WH Neer R Pohl G Adami S Mautalen C Reginster JY Stepan JJ Myers SL Mitlak BH | | 0，，： | 1 |
| 6 | Low potency oestrogen and risk of endo- metrial cancer: a case-control study显示文摘 | Weiderpass E Baron J A Adami H O Magnusson C Lindgren A BergstrOm R | 1999 | Lancet1999，353，18： | 1 |
| 7 | Accelerated aging: Prediction of chemical stability of pharmaceuticals显示文摘 | Waterman K C Adami R C | 2005 | International Journal of Pharmaceutics2005，293，： | 1 |
| 8 | S100B binding to RAGE in microglia stimulates COX-2 expression显示文摘 | Bianchi R Adami C Giambanco I Donato R | 2007 | J Leukoc Biol2007，81，1： | 1 |
| 9 | Denosumab for prevention of fractures in postmenopausal women with osteoporosis显示文摘 | Cummings SR San Martin J McClung MR Siris ES Eastell R Reid IR Delmas P Zoog HB Austin M Wang A Kutilek S Adami S Zanchetta J Libanati C Siddhanti S Christiansen C FREEDOM Trial | | 0，，： | 1 |
| 10 | Effect of risedronate on the risk of hip fracture in elderly women显示文摘 | McClung MR Geusens P Miller P Zippel H Bensen WG Roux C Adami S Fogelman I Diamond T Eastell R Meunier PJ Wasnich RD Greenwald M Kaufman JM Chesnut CH Reginster JY | 2001 | N Engl J Med2001，34，： | 1 |
| 11 | S100B binding to RAGE in microglia stimulates COX-2 expression显示文摘 | Bianchi R Adami C Giambanco I | 2007 | J Leukoc Biol2007，81，1： | 1 |
| 12 | Peptide mediated gene delivery;influence of peptide structure on gene expression显示文摘 | Collard W T Adami R C | 1997 | Bioconjug Chem1997，8，： | 1 |
| 13 | Reduction criterion for separability显示文摘 | CERF N J ADAMI C GINGRICH R M | | 0，，： | 1 |
| 14 | S100B binding to RAGE in microglia stimulates COX-2 expression 显示文摘 | Bianchi R Adami C Giambanco I | 2007 | J Leukoc Biol2007，81，： | 1 |
| 15 | Breast-cancer risk following long-term oestrogen and oestrogen-progestin-replacement therapy 显示文摘 | Magnusson C Baron J A Correia N Bergstrom R Adami H O Persson I | 1999 | Int J Cancer1999，81，： | 1 |
| 16 | Solitary, isolated metastatic disease to the kidney: Memorial Sloan-Kettering Cancer Center experience显示文摘 | Adamy A Von Bodman C Ghoneim T Favaretto R L Bernstein M Russo P | 2011 | BJU Int2011，108，： | 1 |
| 17 | Guidelines for the diagnosis,prevention and treatment of osteoporosis显示文摘 | Adami S Bertoldo F Brandi ML Cepollaro C Filipponi P Fiore E Frediani B Giannini S Gonnelli S Isaia GC Luisetto G Mannarino E Marcocci C Masi L Mereu C Migliaccio S Minisola S Nuti R Rini G Rossini M Varenna M Ventura L Bianchi G | | 0，，： | 1 |
| 18 | S100B-stimulated NO pro duction by BV-2 microglia is independent of RAGE transduc- ing actinity but dependent on RAGE extracellular domain显示文摘 | Adami C Bianchi R Pula G | 2004 | Bioehim Biophys Acta2004，1742，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员